Innovative Laser Procedure Offers New Hope For Recurrent Brain Tumors

High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns aft nan tumor is removed, making it difficult to treat. Patients with recurrent high-grade astrocytoma typically only past for four to 5 months. 

Immune checkpoint inhibitors, medications that let nan body's ain immune system, particularly cancer-fighting T-cells, to recognize, find and onslaught tumor cells, can thief extremity nan recurrence of cancer in galore parts of nan body. 

However, these drugs are not usually effective on encephalon cancers for illustration astrocytoma due to the blood-brain obstruction - a tightly sealed furniture of cells that acts arsenic a protective bound betwixt nan encephalon and nan bloodstream. Because this obstruction is truthful effective, it also limits nan expertise of immune cells, including cancer-fighting T-cells, to participate nan encephalon and scope nan tumor. 

But now, Keck Medicine of USC researchers whitethorn person discovered a measurement to break through this blood-brain obstruction and make immune checkpoint inhibitors effective for patients pinch recurrent, high-grade astrocytoma, thus potentially extending patients' lives. 

Stunning results 

In a Phase 1/2b objective trial, investigators combined a minimally invasive process that uses laser power to both destruct nan tumor insubstantial and disrupt nan blood-brain barrier, with a common immune checkpoint inhibitor drug, pembrolizumab. 

The results, published today in Nature Communications, were striking. Nearly half of patients treated with laser interstitial thermal therapy (LITT), followed by pembrolizumab were still alive at 18 months. In comparison, none of nan patients who received a accepted curen of room followed by pembrolizumab were alive astatine nan 18-month-mark. 

In addition, much than one-third of patients treated pinch LITT and the immune checkpoint inhibitor lived much than 3 years, far exceeding the typical four-to-five-month survival for patients pinch recurrent high-grade astrocytoma. 

These results suggest that LITT tin thief nan immune checkpoint inhibitor pembrolizumab activity much efficaciously against high-grade astrocytoma. Patients pinch this type of precocious crab person fewer remaining options and mediocre outcomes, and this attack could meaningfully extend their survival time and supply caller dream for patients and their loved ones." 

David Tran, MD, PhD, main of neuro-oncology pinch Keck Medicine, co-director of the USC Brain Tumor Center and lead writer of nan study

How LITT breaks through the blood-brain barrier 

Tran and his colleagues based nan study connected their past investigation showing that the power produced by LITT can disrupt nan blood–brain obstruction for several weeks, which is capable time for T-cells to observe and target cancer cells erstwhile they person been activated by an immune checkpoint inhibitor. 

During nan trial, participants received either LITT aliases surgery/biopsy, past nan pembrolizumab. For those receiving LITT, neurosurgeons used magnetic resonance imaging (MRI) to locate the tumor successful nan brain, guide nan LITT probe into nan tumor, then precisely deliver laser heat to nan tumor. The heat destroys nan tumor while surgeons work to ensure nary patient encephalon insubstantial is damaged; and as a broadside product, the heat disrupts nan blood-brain barrier. 

Once patients person the immune checkpoint inhibitor, this disruption allows tumor materials to slip past nan blood-brain obstruction and into nan blood. "This alerts T-cells to nan beingness of nan tumor and provides easy passage of these T-cells to unreserved in, find and onslaught nan tumor," said Tran. 

About nan objective trial 

Forty-five patients enrolled in the study. All trial participants were successful their 2nd recurrence of astrocytoma, with nearly 15% in their 3rd recurrence, meaning nan crab was astatine a very precocious stage. 

The LITT positive pembrolizumab operation was found to be generally safe and well-tolerated. 

Since nan proceedings began, nan U.S. Food and Drug Administration has cleared LITT for treating definite encephalon tumors, and pembrolizumab has been approved for respective cancers. 

Keck Medical Center of USC was 1 of the three clinical trial sites nationwide, alongside researchers from Washington University successful St. Louis and nan University of Florida. 

Other USC authors for nan study include Son B. Le, PhD, adjunct professor of investigation neurological surgery at the Keck School of Medicine of USC; Harshit Manektalia, MS, computational investigation scientist at nan Keck School; and Dongjiang Chen, MD, assistant professor of investigation neurological room astatine nan Keck School.